Todays Report: Today, Boston Common Asset Management LLC Sold shares of Core Laboratories NV (CLB)

Today, Boston Common Asset Management LLC Sold shares of Core Laboratories NV (CLB)

Boston Common Asset Management LLC cut its position in Core Laboratories NV (NYSE:CLB) by 4.6% during the third quarter, Holdings Channel reports. The firm owned 22,002 shares of the company’s stock after selling 1,060 shares during the period. Boston Common Asset Management LLC’s holdings in Core Laboratories NV were worth $2,471,000 at the end of the most recent quarter.

A number of other large investors have also made changes to their positions in CLB. NEXT Financial Group Inc boosted its stake in shares of Core Laboratories NV by 784.3% in the third quarter. NEXT Financial Group Inc now owns 902 shares of the company’s stock worth $101,000 after buying an additional 800 shares during the period. Balentine LLC boosted its stake in shares of Core Laboratories NV by 44.3% in the second quarter. Balentine LLC now owns 893 shares of the company’s stock worth $111,000 after buying an additional 274 shares during the period. MU Investments Co. Ltd. acquired a new stake in shares of Core Laboratories NV during the second quarter worth $115,000. Advisory Services Network LLC boosted its stake in shares of Core Laboratories NV by 33.2% in the third quarter. Advisory Services Network LLC now owns 1,062 shares of the company’s stock worth $119,000 after buying an additional 265 shares during the period. Finally, Daiwa Securities Group Inc. boosted its stake in shares of Core Laboratories NV by 10.0% in the third quarter. Daiwa Securities Group Inc. now owns 1,100 shares of the company’s stock worth $124,000 after buying an additional 100 shares during the period.

Core Laboratories NV (NYSE:CLB) traded down 0.1050% on Friday, reaching $109.0154. 36,846 shares of the company’s stock traded hands. The stock has a market cap of $4.81 billion, a price-to-earnings ratio of 73.8587 and a beta of 1.40. Core Laboratories NV has a 12-month low of $84.50 and a 12-month high of $135.49. The stock has a 50 day moving average price of $106.09 and a 200 day moving average price of $114.64.

Core Laboratories NV (NYSE:CLB) last issued its quarterly earnings data on Wednesday, October 19th. The company reported $0.38 earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of $0.38. Core Laboratories NV had a net margin of 10.17% and a return on equity of 108.46%. The firm had revenue of $143.50 million for the quarter, compared to the consensus estimate of $155.72 million. During the same quarter in the previous year, the firm earned $0.83 EPS. The company’s quarterly revenue was down 27.3% compared to the same quarter last year. Analysts forecast that Core Laboratories NV will post $1.52 EPS for the current year.

The company also recently disclosed a quarterly dividend, which was paid on Tuesday, November 22nd. Stockholders of record on Friday, October 21st were given a $0.55 dividend. This represents a $2.20 dividend on an annualized basis and a dividend yield of 2.02%. The ex-dividend date was Wednesday, October 19th. Core Laboratories NV’s payout ratio is currently 149.66%.

A number of equities research analysts have weighed in on the stock. Zacks Investment Research upgraded shares of Core Laboratories NV from a “sell” rating to a “hold” rating and set a $118.00 price objective on the stock in a report on Monday, October 24th. DA Davidson assumed coverage on shares of Core Laboratories NV in a report on Wednesday, October 5th. They issued a “buy” rating and a $136.00 price objective on the stock. Citigroup Inc. upped their price objective on shares of Core Laboratories NV from $110.00 to $115.00 and gave the stock a “neutral” rating in a report on Tuesday, October 11th. Loop Capital began coverage on shares of Core Laboratories NV in a research note on Friday, September 30th. They issued a “hold” rating and a $120.00 target price on the stock. Finally, Cowen and Company reiterated a “market perform” rating and issued a $105.00 target price on shares of Core Laboratories NV in a research note on Saturday, October 22nd. Three investment analysts have rated the stock with a sell rating, eleven have issued a hold rating and eight have given a buy rating to the company. The stock presently has a consensus rating of “Hold” and an average price target of $121.50.

About Core Laboratories NV

Core Laboratories N.V. is a provider of reservoir description, production enhancement and reservoir management services to the oil and gas industry. The Company’s services and products are directed toward enabling the Company’s clients to improve reservoir performance and increase oil and gas recovery from their producing fields.

Related posts

Leave a Comment